24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways, Nature Reviews Cancer editorial titled “Too Much of a Good Thing”, which explores a counterintuitive cancer therapy approach that underscores the growing promise of its lead compound, LB-100 Nature.

Read more at globenewswire.com